TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11226005

Group type: EXPERIMENTAL
Intervention: Rituximab at escalated doses (initial dose of 375 mg/m2, maximum dose of 2,250 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study: 8776812

Group type: EXPERIMENTAL
Intervention: Leuprolide + flutamide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 150
Study: 1290977

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nalidixic acid
Number of subjects: 17
Study: 6374055

Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin 90 mg/m2 every three weeks (20 patients)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Observation (22 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin
Number of subjects: 42
Study: 31647277

Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Family-enhanced nondirective supportive therapy
Number of subjects: 129
Study: 29546335

Group type: EXPERIMENTAL
Intervention: Transcriptome analysis of the alimentary tract (AT) of Ectropis oblique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative real‐time polymerase chain reaction (qRT-PCR) for 21 selected genes
Number of subjects: 0
Study: 26370923

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/d
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/d plus Metformin 2000 mg/d
Number of subjects: 37
Study: 24423186

Group type: EXPERIMENTAL
Intervention: Intravenous ferrous sucrose (200 mg/24 hours for two consecutive days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 72
Study: 23078574

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (5 cups of 6-ounce cups per day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (5 cups of 6-ounce cups per day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Water (control group, 5 cups of 6-ounce cups per day)
Number of subjects: 42
Study: 21062875

Group type: COMPARATOR
Intervention: Bilateral auscultation of the chest
Number of subjects: 160

Group type: COMPARATOR
Intervention: Observation and palpation of symmetrical chest movements
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Estimation of the position of the tube by the insertion depth
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of all three methods (auscultation, observation, tube depth)
Number of subjects: 160
Study: 17617279

Group type: COMPARATOR
Intervention: Pramlintide 30 to 60 microg QID
Number of subjects: 243

Group type: COMPARATOR
Intervention: Pramlintide 60 microg TID
Number of subjects: 243

Group type: COMPARATOR
Intervention: Pramlintide 60 microg QID
Number of subjects: 243

Group type: COMPARATOR
Intervention: Pramlintide 120 microg BID
Number of subjects: 243

Group type: COMPARATOR
Intervention: Pramlintide 150 microg TID
Number of subjects: 243
Study: 15893085

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standardized Brief Advice (BA)
Number of subjects: 85
Study: 11916764

Group type: EXPERIMENTAL
Intervention: 300 mg DHA + 70 mg EPA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 600 mg DHA + 140 mg EPA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9475137

Group type: EXPERIMENTAL
Intervention: Home program plus supervised rehabilitation (Group S)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Home program (Group H)
Number of subjects: 31
Study: 9185039

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with subconjunctival retention of 0.5 mL pure C3F8 gas (Group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Trabeculectomy alone (Group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 32
Study: 1981075

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg given once a day for 4 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0
Study: 7019300

Group type: EXPERIMENTAL
Intervention: Combination treatment consisting of preliminary chemotherapy (AVM or CMF), radiotherapy, and follow-up adjuvant chemotherapy.
Number of subjects: 74
Study: 30694576

Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 29032921

Group type: EXPERIMENTAL
Intervention: Optimel eye drops (Manuka honey) used twice a day for two weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional lubricant (Systane Ultra) therapy used for two weeks
Number of subjects: 24
Study: 25431280

Group type: EXPERIMENTAL
Intervention: High Intensity (HI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low Intensity with Blood Flow Restriction (LI-BFR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low Intensity (LI)
Number of subjects: 12
Study: 24658707

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human albumin
Number of subjects: 0
Study: 22533900

Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling of moderate-to-vigorous physical activity intervention
Number of subjects: 278

Group type: COMPARATOR
Intervention: Print/website materials-only condition
Number of subjects: 278
Study: 20978545

Group type: EXPERIMENTAL
Intervention: Surgery-based treatment
Number of subjects: 133

Group type: COMPARATOR
Intervention: Radiation-based treatment
Number of subjects: 133
Study: 17079058

Group type: EXPERIMENTAL
Intervention: Aluminum adjuvanted eleven‐valent pneumococcal conjugate vaccine (11PncTD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving only DTwP/PRP‐T
Number of subjects: 0
Study: 16123103

Group type: EXPERIMENTAL
Intervention: Substance P (10 microm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Substance P (20 microm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Substance P + 10 mm L-NAME
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Substance P + 500 microm pyrilamine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Substance P + 10 mm L-NAME + 500 microm pyrilamine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Second dose of Substance P
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control site (Substance P only)
Number of subjects: 15
Study: 12153837

Group type: EXPERIMENTAL
Intervention: Intravenous yohimbine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 30
Study: 10533327

Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol® 200 ug
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol® 400 ug
Number of subjects: 145

Group type: COMPARATOR
Intervention: Combined intramuscular oxytocin and ergometrine (O‐E)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol® (200 ug and 400 ug)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol®
Number of subjects: 145
Study: 8537692

Group type: EXPERIMENTAL
Intervention: 300 units of hyaluronidase per one-half liter
Number of subjects: 25

Group type: COMPARATOR
Intervention: 150 units of hyaluronidase per one-half liter
Number of subjects: 25
Study: 2261719

Group type: EXPERIMENTAL
Intervention: Morning barium meal examinations
Number of subjects: 60

Group type: COMPARATOR
Intervention: Afternoon barium meal examinations
Number of subjects: 60
Study: 542823

Group type: EXPERIMENTAL
Intervention: Björk-Shiley (B-S) valves
Number of subjects: 79

Group type: COMPARATOR
Intervention: Lillehei-Kaster (L-K) valves
Number of subjects: 79
Study: 31834252

Group type: COMPARATOR
Intervention: Statins (10 mg of rosuvastatin)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo + Exercise Training (PLET)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Statins + Exercise Training (STAET)
Number of subjects: 83
Study: 30589927

Group type: EXPERIMENTAL
Intervention: Creation of subperiosteal tunnels prior to lateral osteotomies
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control side (without creation of subperiosteal tunnels)
Number of subjects: 34
Study: 28120631

Group type: EXPERIMENTAL
Intervention: Multicomponent dyadic intervention including physical exercise and support
Number of subjects: 111

Group type: COMPARATOR
Intervention: Minimal intervention (monthly written information bulletins and monthly phone calls)
Number of subjects: 111
Study: 26433799

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (8 sessions, twice a week for 4 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg three times a day for 10 days)
Number of subjects: 50
Study: 23884046

Group type: EXPERIMENTAL
Intervention: 4-week educational intervention involving weekly 60-minute sessions (Group A)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 13
Study: 21911858

Group type: EXPERIMENTAL
Intervention: Free Play (FP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1 touch (1T)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2 touches (2T)
Number of subjects: 20
Study: 20011748

Group type: EXPERIMENTAL
Intervention: Brushing Index (BI2) after Gingival Bleeding Index (GBI1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Brushing Index (BI1) before Gingival Bleeding Index (GBI2)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gingival Bleeding Index (GBI1) and Brushing Index (BI2)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Brushing Index (BI1) and Gingival Bleeding Index (GBI2)
Number of subjects: 34
Study: 17395677

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg daily
Number of subjects: 2755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2755
Study: 15132341

Group type: EXPERIMENTAL
Intervention: HELP clinic evaluation (full evaluation)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: HELP clinic evaluation (some components)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: HELP clinic evaluation (only primary care appointment)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Health behavior counseling
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Primary care visits after HELP clinic contact
Number of subjects: 235
Study: 11133617

Group type: EXPERIMENTAL
Intervention: Hi‐Contour Cuff
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Profile Soft‐Seal Cuff
Number of subjects: 50

Group type: COMPARATOR
Intervention: All groups (Hi‐Contour, Sheridan, Rush, Reinforce, Profile Soft‐Seal Cuff)
Number of subjects: 50
Study: 9754454

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10695381

Group type: EXPERIMENTAL
Intervention: Noradrenaline concentration in blood serum
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic hormone concentration in blood serum
Number of subjects: 9
Study: 2223154

Group type: EXPERIMENTAL
Intervention: Adjuvant oral bestatin treatment (30 mg daily for at least 1 year)
Number of subjects: 194

Group type: COMPARATOR
Intervention: No bestatin (Control)
Number of subjects: 194
Study: 631993

Group type: EXPERIMENTAL
Intervention: Group A (dialyzed on Mondays and Thursdays)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Group B (dialyzed on Tuesdays and Fridays)
Number of subjects: 21
Study: 31119689

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 10 mg/160 mg + rosuvastatin 20 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 57
Study: 27774609

Group type: EXPERIMENTAL
Intervention: Telephone call reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text message reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Letter reminder
Number of subjects: 0
Study: 25804297

Group type: EXPERIMENTAL
Intervention: Facilitated exercise intervention (usual care plus exercise support)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 94
Study: 23422495

Group type: EXPERIMENTAL
Intervention: Everolimus 3-8 ng/mL
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Everolimus 6-12 ng/mL
Number of subjects: 833

Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA) 1.44 g per day
Number of subjects: 833
Study: 22159930

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 19767606

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 151
Study: 17182126

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF) treatment started within 24 hours after PCI.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no G‐CSF treatment).
Number of subjects: 40
Study: 14996877

Group type: EXPERIMENTAL
Intervention: Deflazacort (treatment group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 54
Study: 11323510

Group type: EXPERIMENTAL
Intervention: Frozen-section analysis
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-frozen-section analysis
Number of subjects: 61
Study: 9643615

Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Capsaicin pretreatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 15
Study: 7943585

Group type: EXPERIMENTAL
Intervention: Stripping
Number of subjects: 156

Group type: COMPARATOR
Intervention: High ligation combined with sclerotherapy
Number of subjects: 156
Study: 2816806

Group type: EXPERIMENTAL
Intervention: Cocoa butter
Number of subjects: 6

Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 6
Study: 31546738

Group type: EXPERIMENTAL
Intervention: Domestic indoor air monitoring and 24 h ambulatory monitoring of peripheral and central blood pressure, measures of central hemodynamic indices, standardized questionnaires, 24 h time-activity diary, clinic-based health assessment including blood and urine biomarkers for lipid and glucose profiles, renal function measures, central pulse wave and pulse wave velocity analysis.
Number of subjects: 111
Study: 28454836

Group type: EXPERIMENTAL
Intervention: Losartan (150 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25942666

Group type: EXPERIMENTAL
Intervention: Body Cream (moisturizer group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Flare Treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (cleanser only)
Number of subjects: 45
Study: 22804902

Group type: EXPERIMENTAL
Intervention: Custom-made thumb splint
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prefabricated thumb splint
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no splint)
Number of subjects: 35
Study: 21477419

Group type: EXPERIMENTAL
Intervention: mebeverine hydrochloride plus CBT
Number of subjects: 149

Group type: COMPARATOR
Intervention: mebeverine hydrochloride alone
Number of subjects: 149
Study: 19210159

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 7797

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 7797

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 7797

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 7797

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 7797

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 7797
Study: 16838234

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (4.5 g every 6 h)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Cefepime (2 g every 8 h)
Number of subjects: 528
Study: 12684731

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10851204

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 3610

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 3610

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 3610
Study: 9366936

Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 24
Study: 8258085

Group type: EXPERIMENTAL
Intervention: Transcutaneous cranial electrical stimulation with Limoge currents
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epidural bupivacaine administration
Number of subjects: 120
Study: 3884083

Group type: EXPERIMENTAL
Intervention: Laparotomy at a mean of 6.9 days after emergency admission
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Biliary tract investigations during the first week following admission
Number of subjects: 55
Study: 31446217

Group type: EXPERIMENTAL
Intervention: Negative symptoms (especially asociality and avolition)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarker interleukin-2
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Previous functioning and baseline cognitive performance in attention and vigilance
Number of subjects: 73
Study: 29909285

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/d)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 118
Study: 26927363

Group type: EXPERIMENTAL
Intervention: Triple-site stimulation (left dorsolateral prefrontal stimulation, 1000 pulses, 20 Hz plus left and right temporoparietal stimulation, 1000 pulses each, 1 Hz)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Single-site stimulation (left temporoparietal stimulation, 3000 pulses, 1 Hz)
Number of subjects: 49
Study: 25406842

Group type: EXPERIMENTAL
Intervention: Dedicated Education Unit (DEU) clinical model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Practice partners' feedback
Number of subjects: 0
Study: 22724115

Group type: EXPERIMENTAL
Intervention: Two-step self-etching adhesive AdheSE (AS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Two-step etch-and-rinse adhesive Excite (EX)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SEM analysis
Number of subjects: 50
Study: 20096379

Group type: EXPERIMENTAL
Intervention: Harvey‐Bradshaw Index
Number of subjects: 1000
Study: 18724188

Group type: EXPERIMENTAL
Intervention: Eban HIV/STD Risk Reduction Intervention (treatment)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Eban Health Promotion Intervention (control)
Number of subjects: 535
Study: 15862509

Group type: EXPERIMENTAL
Intervention: RayGel (reduced glutathione and anthocyanins)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12434307

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% gel forming solution (TXE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Timolol maleate 0.5% gel forming solution (TXG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both TXE and TXG
Number of subjects: 32
Study: 10483663

Group type: EXPERIMENTAL
Intervention: Standing distance from the stair
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stair heights representing 83% and 93% of each group's mean leg length
Number of subjects: 20
Study: 8960832

Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CPII) for 12 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 18
Study: 2022266

Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine (2.5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral bromocriptine (2.5 mg)
Number of subjects: 8
Study: 6350743

Group type: EXPERIMENTAL
Intervention: Chest radiographs ordered by physicians
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Chest radiographs not ordered by physicians
Number of subjects: 2018
Study: 25555626

Group type: EXPERIMENTAL
Intervention: Book intervention (provision of a booklet with evidence-based information)
Number of subjects: 52075

Group type: EXPERIMENTAL
Intervention: School-level interventions (book and/or feedback of names of children with high levels of ADHD symptoms)
Number of subjects: 52075

Group type: EXPERIMENTAL
Intervention: Baseline inattention
Number of subjects: 52075

Group type: EXPERIMENTAL
Intervention: Baseline impulsiveness
Number of subjects: 52075
Study: 30601979

Group type: EXPERIMENTAL
Intervention: 6-week health program
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (no health program)
Number of subjects: 229
Study: 28577671

Group type: EXPERIMENTAL
Intervention: Aspirin + prasugrel
Number of subjects: 3539

Group type: COMPARATOR
Intervention: Aspirin + clopidogrel
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: Insulin treatment in patients with DM
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: Prasugrel vs. clopidogrel
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: Insulin treatment among DM patients
Number of subjects: 3539
Study: 26096546

Group type: EXPERIMENTAL
Intervention: Real feedback group (rFB, n=13)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Yoke feedback group (yFB, n=13)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Passive control group (noFB, n=12)
Number of subjects: 38
Study: 25028542

Group type: EXPERIMENTAL
Intervention: Reasoning Exercises in Assisted Living (REAL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Attention control (vitamin education)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 13
Study: 22005107

Group type: EXPERIMENTAL
Intervention: ELTGOL (slow expiration with glottis opened in lateral posture)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (ventilatory scintigraphy measurements only)
Number of subjects: 12
Study: 18836778

Group type: EXPERIMENTAL
Intervention: Controlled-flow vacuum-free bottle system (CFVFB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard bottle (SB)
Number of subjects: 30
Study: 17900394

Group type: EXPERIMENTAL
Intervention: i.v. topotecan
Number of subjects: 211

Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and vincristine
Number of subjects: 211
Study: 15221507

Group type: EXPERIMENTAL
Intervention: Taurine 3 g/day for 7 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 7 weeks
Number of subjects: 30